JP5543982B2 - Ｃｏｐｄの処置に有用な５−ピラゾリル−２−ピリドン誘導体のトシル酸塩 - Google Patents

Ｃｏｐｄの処置に有用な５−ピラゾリル−２−ピリドン誘導体のトシル酸塩 Download PDF

Info

Publication number
JP5543982B2
JP5543982B2 JP2011550649A JP2011550649A JP5543982B2 JP 5543982 B2 JP5543982 B2 JP 5543982B2 JP 2011550649 A JP2011550649 A JP 2011550649A JP 2011550649 A JP2011550649 A JP 2011550649A JP 5543982 B2 JP5543982 B2 JP 5543982B2
Authority
JP
Japan
Prior art keywords
compound
tosylate
parts
methyl
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011550649A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012518623A (ja
Inventor
マリー−リュヌ・アルカラ
ラーシュ−エリク・ブリッグネル
ペール・トーマス・クリングステッド
ハンス・ローラント・レン
ヘレナ・ニックラーション
ロバート・アンソニー・ニクソン
アンドリュー・ジェイムズ・ワッツ
ロベルト・ズバン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42046174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5543982(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2012518623A publication Critical patent/JP2012518623A/ja
Application granted granted Critical
Publication of JP5543982B2 publication Critical patent/JP5543982B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2011550649A 2009-02-20 2010-02-18 Ｃｏｐｄの処置に有用な５−ピラゾリル−２−ピリドン誘導体のトシル酸塩 Active JP5543982B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15409909P 2009-02-20 2009-02-20
US61/154,099 2009-02-20
PCT/GB2010/050271 WO2010094964A1 (en) 2009-02-20 2010-02-18 Tosylate salt of a 5-pyrazolyl-2-pyridone derivative, useful in the treatment of copd

Publications (2)

Publication Number Publication Date
JP2012518623A JP2012518623A (ja) 2012-08-16
JP5543982B2 true JP5543982B2 (ja) 2014-07-09

Family

ID=42046174

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011550649A Active JP5543982B2 (ja) 2009-02-20 2010-02-18 Ｃｏｐｄの処置に有用な５−ピラゾリル−２−ピリドン誘導体のトシル酸塩

Country Status (15)

Country Link
US (2) US8232296B2 (pt)
EP (1) EP2398792B1 (pt)
JP (1) JP5543982B2 (pt)
KR (1) KR20110127158A (pt)
CN (1) CN102405219B (pt)
AR (1) AR075523A1 (pt)
AU (1) AU2010215269B2 (pt)
BR (1) BRPI1008396B8 (pt)
CA (1) CA2752319C (pt)
ES (1) ES2469916T3 (pt)
MX (1) MX2011008389A (pt)
RU (1) RU2526038C2 (pt)
TW (1) TW201036957A (pt)
UY (1) UY32461A (pt)
WO (1) WO2010094964A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
TW200808763A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
TW200808771A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
WO2009061271A1 (en) * 2007-11-06 2009-05-14 Astrazeneca Ab Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
EP2671614A1 (en) * 2007-12-21 2013-12-11 University of Rochester Molecular Targets for Treatment of Inflammation
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
CA2773618A1 (en) * 2009-10-02 2011-04-07 Astrazeneca Ab 2-pyridone compounds used as inhibitors of neutrophil elastase
US9475041B2 (en) 2012-04-24 2016-10-25 Basf Se Zeolitic materials and methods for their preparation using alkenyltrialkylammonium compounds
US20140057920A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US9102624B2 (en) 2012-08-23 2015-08-11 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057926A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US9744526B2 (en) * 2012-09-26 2017-08-29 Dalian Institute Of Chemical Physics, Chinese Academy Of Sciences SAPO-34 molecular sieve and method for preparing the same
KR101652209B1 (ko) * 2012-09-26 2016-08-29 달리안 인스티튜트 오브 케미컬 피직스, 차이니즈 아카데미 오브 사이언시즈 Sapo-34 분자체 및 그 합성 방법
ES2634020T3 (es) * 2013-03-06 2017-09-26 Novartis Ag Formulaciones de compuestos orgánicos
RU2542100C1 (ru) * 2013-12-24 2015-02-20 Федеральное государственное бюджетное учреждение науки Институт химии растворов им. Г.А. Крестова Российской Академии Наук (ИХС РАН) Сокристаллическая форма теофиллина с дифлунисалом или диклофенаком
US9221807B2 (en) * 2014-02-21 2015-12-29 Boehringer Ingelheim International Gmbh Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity
WO2016128917A1 (en) * 2015-02-12 2016-08-18 Basf Se Process for the preparation of a dealuminated zeolitic material having the bea framework structure
US20160257573A1 (en) * 2015-03-03 2016-09-08 Uop Llc High surface area pentasil zeolite and process for making same
CN109890385B (zh) * 2016-10-28 2022-08-02 阿斯利康(瑞典)有限公司 (1r,2r)-2-[4-(3-甲基-1h-吡唑-5-基)苯甲酰基]-n-(4-氧代-4,5,6,7-四氢吡唑并[1,5-a]吡嗪-3-基)环己烷甲酰胺的结晶形式
CN114650819A (zh) * 2019-09-17 2022-06-21 美莱奥生物制药第四有限公司 用于治疗移植物排斥、闭塞性细支气管炎综合征和移植物抗宿主病的阿维来司他
CN112851643B (zh) * 2019-11-28 2024-01-16 广东东阳光药业股份有限公司 嘧啶苯甲酰胺化合物的盐酸盐及其用途
WO2021209740A1 (en) 2020-04-16 2021-10-21 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
CN114075135B (zh) * 2020-08-10 2024-06-11 上海润石医药科技有限公司 含邻氨基吡啶炔基的化合物的盐及其制备方法和应用
AU2022214610A1 (en) * 2021-01-27 2023-07-27 Intra-Cellular Therapies, Inc. Salt crystals
EP4419102A1 (en) 2021-10-20 2024-08-28 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis
WO2023115795A1 (zh) * 2021-12-23 2023-06-29 深圳安泰维生物医药有限公司 一种核苷类化合物的晶型
WO2025078838A1 (en) 2023-10-11 2025-04-17 Mereo Biopharma 4 Limited Alvelestat and alpha- 1 antitrypsin for treating respiratory disorders
WO2025133628A1 (en) 2023-12-21 2025-06-26 Mereo Biopharma 4 Limited Use of alvelestat in specific patients
GB202319953D0 (en) 2023-12-22 2024-02-07 Mereo Biopharma 4 Ltd Tablet formulations involving alvelestat

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2358891A1 (fr) * 1976-07-22 1978-02-17 Yamanouchi Pharma Co Ltd Composes heterocycliques contenant un azote, utilise comme agents analgesiques et anti-inflammatoires
DE2706977A1 (de) * 1977-02-18 1978-08-24 Hoechst Ag Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung
EP0008864A1 (en) 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
JPH02152966A (ja) 1988-12-05 1990-06-12 Otsuka Pharmaceut Co Ltd ４−ヒドロキシカルボスチリル誘導体
US5521179A (en) * 1991-04-18 1996-05-28 Zeneca Limited Heterocyclic amides
US5441960A (en) * 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
IL130181A0 (en) 1996-12-05 2000-06-01 Amgen Inc Substituted pyrimidone and pyridone compounds and methods of use
JPH1171351A (ja) * 1997-08-29 1999-03-16 Ss Pharmaceut Co Ltd 置換キノロン誘導体及びこれを含有する医薬
IL152848A0 (en) 2000-06-12 2003-06-24 Eisai Co Ltd 1,2-dihydropyridine derivatives, pharmaceutical compositions containing the same and methods for the production thereof
ES2330719T3 (es) * 2000-12-28 2009-12-15 SHIONOGI & CO., LTD. Derivados de 2-piridona con afinidad para el receptor cannabinoide de tipo 2.
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
BR0211900A (pt) * 2001-08-14 2004-08-24 Toyama Chemical Co Ltd Método para inibição do desenvolvimento de vìrus e/ou virucida, análogos de nucleotìdeo de pirazina e de nucleosìdeo de pirazina, precursor do inibidor da polimerase de rna, inibidor da polimerase de rna, método para tratar pacientes infectados por vìrus, e, usos de um análogo de nucleotìdeo de pirazina ou um sal deste e de um análogo de nucleosìdeo de pirazina ou um sal deste
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
SE0104251D0 (sv) 2001-12-14 2001-12-14 Astrazeneca Ab Novel compounds
GB2383326A (en) 2001-12-20 2003-06-25 Bayer Ag Antiinflammatory dihydropyridines
MXPA03000145A (es) * 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
PT1477186E (pt) * 2002-02-19 2010-02-11 Shionogi & Co Antipruriginosos
JP4619122B2 (ja) 2002-08-27 2011-01-26 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｈｎｅインヒビターとしてのジヒドロピリジノン誘導体
GB2392910A (en) 2002-09-10 2004-03-17 Bayer Ag 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
EP1598349B1 (en) 2003-02-13 2011-07-27 Msd K.K. Novel 2-pyridinecarboxamide derivatives
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP4767842B2 (ja) 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
DE602004021921D1 (de) 2003-05-28 2009-08-20 Theravance Inc Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
SE0302324D0 (sv) * 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302323D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302487D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
US7345060B2 (en) 2003-11-21 2008-03-18 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
JP5134248B2 (ja) 2004-02-19 2013-01-30 バイエル・ファルマ・アクチェンゲゼルシャフト ジヒドロピリジノン誘導体
CA2557271C (en) 2004-02-26 2012-08-21 Bayer Healthcare Ag 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors
DE102004024453A1 (de) 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7569586B2 (en) 2004-08-16 2009-08-04 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
JP2008510014A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
US7605168B2 (en) 2004-09-03 2009-10-20 Plexxikon, Inc. PDE4B inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TW200843761A (en) * 2004-10-28 2008-11-16 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
TW200700392A (en) * 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0512940D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Compounds and their use
BRPI0614290A2 (pt) 2005-08-08 2011-03-22 Argenta Discovery Ltd derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
GB0605469D0 (en) 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
RS20080411A (sr) 2006-03-20 2009-07-15 Pfizer Limited, Derivati amina
NZ572250A (en) 2006-05-04 2011-10-28 Pulmagen Therapeutics Inflammation Ltd Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
GB0613154D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
BRPI0714409A2 (pt) 2006-07-14 2013-03-12 Novartis Ag derivados de pirimidina como inibidores de alk-5
BRPI0714463A2 (pt) 2006-07-19 2013-04-02 Astrazeneca Ab compostos de espiropiperidina tricÍclicos, sua sÍntese e seus usos como moduladores de atividade receptora de quimiocina
US20110003858A1 (en) * 2006-09-04 2011-01-06 Bergstroem Lena Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
AP2009004791A0 (en) 2006-10-04 2009-04-30 Pfizer Ltd Sulfonamide derivatives as adrenergic agonists andmuscarinic antagonists
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
AU2007336054A1 (en) 2006-12-19 2008-06-26 Astrazeneca Ab Quinuclidinol derivatives as muscarinic receptor antagonists
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
SA08280783B1 (ar) 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
BRPI0807004A2 (pt) 2007-02-07 2014-04-15 Argenta Discovery Ltd Sal
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
KR20090110353A (ko) 2007-02-15 2009-10-21 아젠터 디스커버리 리미티드 Ｍ３ 무스카린 수용체로서의 헤테로시클릭 유도체
WO2008104752A1 (en) 2007-02-26 2008-09-04 Astrazeneca Ab Dihydropyridones as elastase inhibitors
EP2170848B1 (en) 2007-06-27 2014-10-22 AstraZeneca AB Pyrazinone derivatives and their use in the treatment of lung diseases
WO2009058076A1 (en) 2007-11-02 2009-05-07 Astrazeneca Ab 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
WO2009061271A1 (en) 2007-11-06 2009-05-14 Astrazeneca Ab Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
HRP20120968T1 (hr) 2008-02-06 2013-01-31 Astrazeneca Ab Spojevi
EA017627B1 (ru) 2008-05-13 2013-01-30 Астразенека Аб Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора
GB0811099D0 (en) 2008-06-17 2008-07-23 Astrazeneca Ab New combination 376
US7862384B2 (en) * 2008-07-07 2011-01-04 Myers Kelly H Repair adapter for a modular plug
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628

Also Published As

Publication number Publication date
EP2398792A1 (en) 2011-12-28
JP2012518623A (ja) 2012-08-16
EP2398792B1 (en) 2014-04-09
RU2526038C2 (ru) 2014-08-20
UY32461A (es) 2010-09-30
AR075523A1 (es) 2011-04-06
AU2010215269B2 (en) 2013-06-27
CN102405219A (zh) 2012-04-04
BRPI1008396B8 (pt) 2021-05-25
WO2010094964A1 (en) 2010-08-26
CA2752319A1 (en) 2010-08-26
CN102405219B (zh) 2013-11-06
KR20110127158A (ko) 2011-11-24
CA2752319C (en) 2016-10-04
US8232296B2 (en) 2012-07-31
ES2469916T3 (es) 2014-06-20
US20120269872A1 (en) 2012-10-25
BRPI1008396B1 (pt) 2020-11-10
MX2011008389A (es) 2011-09-01
HK1162498A1 (en) 2012-08-31
TW201036957A (en) 2010-10-16
BRPI1008396A2 (pt) 2017-06-27
US20100216843A1 (en) 2010-08-26
AU2010215269A1 (en) 2011-08-25
RU2011135627A (ru) 2013-03-27

Similar Documents

Publication Publication Date Title
JP5543982B2 (ja) Ｃｏｐｄの処置に有用な５−ピラゾリル−２−ピリドン誘導体のトシル酸塩
US11760726B2 (en) Crystalline solid forms of N-{4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl} -n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
CN101001629B (zh) 药物组合物
EP2459555B1 (en) Processes for crystallization of rivaroxaban
AU2020276695A1 (en) New crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as Raf inhibitors for the treatment of cancer
WO2011095059A1 (zh) 达沙替尼多晶型物及其制备方法和药物组合物
EP1870400A1 (en) Salts and crystalline salt forms of an 2-indolinone derivative
WO2015108038A1 (ja) エチレングリコール化合物
KR102572035B1 (ko) 무정형 형태의 빌란테롤 트리페나테이트 및 이의 제조방법
US20240228438A1 (en) Solid forms of salts of 4-[5-[(3s)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2- hydroxy-2-ethylpropyl)phenyl]phenyl]-2-fluoro-benzonitrile
KR20260042158A (ko) 메닌 억제제를 포함하는 약학적 조성물
TWI677494B (zh) 製造具有經控制氯含量之阿拉莫林鹽酸鹽（ａｎａｍｏｒｅｌｉｎ ｈｙｄｒｏｃｈｌｏｒｉｄｅ）之方法
JP2008501024A (ja) 混合コクリスタルおよびそれを含んでなる製薬学的組成物
EP3849977B1 (en) Improved method for the manufacture of 3-[(1s)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof
US20240293420A1 (en) Pharmaceutical composition, preparation, and preparation method therefor and use thereof
KR20250155619A (ko) 결정질 형태
JP2019530719A (ja) ４−（２−（（１ｒ，２ｒ）−２−ヒドロキシシクロヘキシルアミノ）ベンゾチアゾール−６−イルオキシ）−ｎ−メチルピコリンアミドの結晶形
HK1162498B (en) Tosylate salt of a 5-pyrazolyl-2-pyridone derivative, useful in the treatment of copd
HK40127061A (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
HK40082657B (zh) 一种药物组合物、制剂及其制备方法和应用
HK40082657A (en) Pharmaceutical composition, formulation thereof, preparation method therefor and use thereof
HK40040786A (en) Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
HK40065390B (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
HK40065390A (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131211

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140331

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140422

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140509

R150 Certificate of patent or registration of utility model

Ref document number: 5543982

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250